This study examined the efficacy of 10 % imidacloprid + 2.5 % moxidectin topical solution (Advantage ® Multi, Advocate ® , Bayer) for the treatment of circulating microfilariae from dogs naturally infected with Dirofilaria immitis. The study included two groups of 11 dogs each that consisted of two replicates. Replicate 1 contained 12 dogs (6 treated and 6 controls) and replicate 2 contained 10 dogs (5 treated and 5 controls). Six of the 10 dogs in replicate 2 were the controls from replicate 1. All dogs entering the study completed a physical examination including chest radiographs, blood collections for examination of Dirofilaria immitis circulating microfilariae, serum chemistry, complete blood counts and urinalysis. To qualify for the study each dog was required to have a geometric mean ≥ 300 microfilariae per ml of blood from 3 consecutive samples collected during the 8 day acclimation period and a heartworm disease classification of 1 or 2. Dogs were treated on study days 0 and 28. Post-treatment microfilarial counts were performed on study days 1, 2, 3, 7, 14, 21, 28, 29, 35, and 42. Percent microfilarial reduction was determined by comparing the geometric mean number of circulating microfilaria remaining in treated dogs with those remaining in the control dogs post-treatment. Seven days after the first treatment, the geometric mean microfilarial counts in treated dogs were reduced by > 99 % compared to the control dogs. Reduction remained at > 99 % through the end of the study at 42 days after the first treatment (14 days after the second treatment). The results of this study demonstrated that Advantage ® Multi for dogs is effcacious for treatment of circulating D. immitis microfilariae in naturally infected heartworm-positive dogs with no treatment-related adverse events observed.
Introduction
The removal of Dirofilaria immitis circulating microfilariae in conjunction with or following the administration of an adulticide is of paramount importance for improving the clinical condition of the dog and mitigating the spread of heartworm infection (McCall et al 2014) . Topically applied Advantage ® Multi for Dogs received additional label claims for "the treatment of Dirofilaria immitis circulating microfilariae in heartwormpositive dogs and the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis" (Supplemental NADA 141 -251 approved October 24, 2013) . These claims were added to the original approved claims for killing adult fleas and the treatment and control of nematode infections, including fourth-stage larvae, immature adults, and adult stages of Ancylostoma caninum and Uncinaria stenocephala, fourth-stage larvae and adult Toxocara canis and adult Toxascaris leonina and Trichuris vulpis. The label also includes monthly use for preventing the development of canine heartworm disease caused by Dirofilaria immitis (Arther et al. 2005) . The supporting data for this product for the treatment of dogs for microfilariae following transplantation of adult D. immitis (Pepper strain, TRS Labs, Inc, Athens, GA) has previously been reported (McCall et al. 2014) . In addition, a clinical field study for further safety and efficacy evaluation was performed at clinical sites in Alabama, Louisiana, Missouri, Oklahoma, Tennessee, and Texas where the product was used alone or in conjunction with melarsomine dihydrochloride for removal of adult worms (Supplemental NADA 141 -251 approved October 24, 2013) . The objective of the study reported here was to evaluate the efficacy of Advantage ® Multi for Dogs for the treatment of circulating D. immitis microfilariae at the minimal labelled dose of 0.1 ml per kilogram body weight for naturally heartworm infected dogs held under laboratory conditions.
Materials and Methods

Animals
Twenty-two (22) dogs obtained from different USDA licensed (U.S. Department of Agriculture (USDA) Animal Welfare Act (9 CFR Parts 1, 2, and 3) sources, that were demonstrated to have adequate pre-treatment mean circulating D. immitis microfilariae (mff) counts of ≥ 300 mff per ml of blood, were included in the study and were randomised to two groups of 11 animals per group. Animals were acclimatised at the facility at least 8 days prior to enrollment. General health observations were conducted once daily. During the acclimatisation period, urinalysis was performed and blood was collected for serum chemistry, CBC (complete blood count), and for quantification of circulating mff using the modified Knott's test (Bowman 2009 ). In addition, pre-treatment chest radiographs were performed and body weights were collected. These tests and examinations were used to determine the heartworm disease classification for each dog. Only dogs with a heartworm disease Classification of 1 or 2 were included in the study (American Heartworm Society 2012; Louisiana State University School of Veterinary Medicine 2015). The dogs were housed in raised stainless steel pens in climate controlled rooms. The space allocation for each animal was in accordance with pertinent animal welfare guidelines or regulations set forth by the USDA. All pens were enclosed on top. Polypropylene dividers prevented animal to animal contact and cross contamination between pens. Dogs were fed a daily ration of commercial dog food containing 21 % protein (River Run, Cargill Animal Nutrition, Minneapolis, MN) and provided water ad libitum. Pens were cleaned daily. Temperature and relative humidity were recorded once daily using maximum-minimum thermometers and a portable digital thermo-hygrometer. The temperatures and relative humidity were normal during the study. Each pen was identified with the animal ID, study number and gender. Lighting was provided by overhead fluorescent lamps, and an automatic timer provided approximately 12 hours of light and 12 hours of darkness each day. General health observations were conducted daily beginning on studay day (SD) -8. The animals were maintained with due regard for their welfare and in accordance with applicable laws, regulations and guidelines. The protocol was approved by the Institutional Care and Use Committee prior to initiation of the study. The study was conducted in accordance with the principles of FDA Guidance for Industry 85, Good Clinical Practice, VICH GL9, May 2001.
Study Design
This study was conducted utilising two replicates. Replicate 1 included 12 dogs. Replicate 2 included 10 dogs (6 of these were dogs from the control group utilised from the completed Replicate 1) ( Table 1 ). All dogs received a physical examination and were weighed during acclimatisation on SD -7 in Replicate 1 and SD -8 in Replicate 2. Animals were randomised on SD -1, by mean pretreatment mff counts to one of two study groups. Three pre-treatment mff counts were performed for each dog using the modified Knott's test on SDs -6, -5 and -4 (Replicate 1) and -8, -7 and -6 (Replicate 2) ( Table 2) . Dogs with pre-treatment mean counts of at least 300 mff per mL that also met the other inclusion criteria were ranked highest to lowest by their mean pre-treatment mff counts. The first 2 dogs (highest counts) were assigned to Set 1, the next 2 dogs were assigned to Set 2, and so forth, until the final 2 dogs (lowest counts) were assigned to Set 6 for Replicate 1. This same allocation method was utilised for Replicate 2, Sets 1 through 5.
Within the two replicates, animals in Group 1 (treated dogs) were treated twice (once on SD 0 and once on SD 28) with Advantage ® Multi for dogs at the minimum label dose (0.1 ml per kilogram body 
Microfilarial counts
Microfilariae were counted using the modified Knott's test (Bowman 2009 ). Briefly after the Knott's sedimentation was performed, the volume in the tube was adjusted to 1 ml with 2 % formalin. Then 20 µl of the mixed 1 ml was examined for microfilariae, and, if mff were found, the count was multiplied by 50 to give the number per ml. If no mff were observed, an additional 100 µl was examined, and, if mff were found, the count was multiplied by 8.33 to determine the number of mff per ml. If no microfilariae were seen in the first 120 µl volume, the entire sediment was examined with the total number of mff observed considered to be the number of mff per ml.
Data Analysis
Percent mff reduction was determined by comparing the geometric mean number of circulating mff remaining in Group 1 with the mff counts remaining in Group 2 at post-treatment intervals on SDs 1, 2, 3, 7, 14, 21, 28, 35, and 42. The graph with mean and 95 % confidence intervals in Figure 1 was created by Prism version 6.04, January 17, 2014, GraphPad Software, Inc.
The analysis consisted of a hierarchical assessment, using the microfilarial counts made on samples collected on SDs 28 and 42. The assumption was, that the counts collected from samples on the treated animals on these two days would have 90 % or greater reduction of the mff compared to the animals in the control group. For the statistical comparisons, the microfilarial counts were transformed [log(counts+1)] and analysed with an analysis of covariance (ANCOVA) including terms for treatment (TRT) (fixed), and block and animal (random), using the average of the log(pre-treatment count+1) values as a covariate. SAS PROC MIXED (SAS ® version 9.2, SAS ® Institute, Cary, NC) was used. The TRT main effect was evaluated.
Comparisons were made between the treatment groups using LSMEANS, (p ≤ 0.05, two-sided).
To provide substantial evidence of the effectiveness of topically applied Advantage ® Multi for Dogs in a laboratory setting, a mff percent reduction of 90 % or greater and a statistically significant difference between the control and treated groups was required at SD 42 and/or 28, and at least 6 of the animals in the control group were required to have an adequate infection of ≥ 300 mff/mL on SD 42 and/or 28.
The efficacy evaluation was based on the percent reduction of the geometric mean mf counts for Advantage ® Multi for Dogs treated dogs when compared to the control dogs topically treated with mineral oil for each post-treatment mff count. Percent efficacy (or percent mff reduction) was determined by comparing the geometric mean mff counts recorded for the IVP treated groups to the geometric mean mff counts recorded for the control group using Abbott's formula:
% Efficacy = (N1-N2)/N1 x 100 N1: Geo. mean mff count (Control) N2: Geo. mean mff count (Treated) 
Results
Microfilariae counts for the three blood samples collected prior to the first treatment ranged from 500 to 33,583 mff per ml (Table 2 ). In the control dogs, at 3 days after the mineral oil application, the mff counts ranged from 500 to 36450 mff per ml, while the counts in the treated dogs ranged from 54 to 7,700 mff per ml. A week after the first treatment, the counts in the control dogs ranged from 200 to 33,600 mff per ml while the counts in the Advantage ® Multi for dogs treated dogs decreased to 0 to 648 mff per ml. By the day of the second treatment on SD 28, the counts in the control dogs ranged from 200 to 27,500 mff per ml, while in the treated dogs the counts ranged between 0 to 30 mff per ml with 5 of the 11 dogs having microfilariae. On SD 42, the last day of sampling, only one treated dog had microfilaria (17 mff per ml), while all control dogs remained positive with a range of 250 to 27,450 mff per ml. Based on the log10 conversion of the mff counts a 3 log reduction in circulating mff was achieved by SD 14 while the mff were almost totally absent on SD 42 in dogs treated with Advantage ® Multi for dogs (Fig. 1 ).
The data demonstrate that mff counts in the treated dogs were statistically reduced as compared to the control dogs on SDs 28 and 42, with 10 of the 11 control dogs with mff counts > 300 mff per ml on Study Day 42. In this study, mff counts in the treated dogs were reduced by > 99 % by SD 7, following one topical treatment with Advantage ® Multi for dogs compared to the control dogs that received mineral oil as a treatment with the microfilarial reduction remaining > 99 % through SD 42 (Table 3 ). The dogs treated with Advantage ® Multi for dogs had significantly (p < 0.05) fewer microfilariae as compared to the control dogs on SDs 28 and 42.
No adverse events were observed which were considered to be treatment related.
Discussion
Advantage ® Multi for Dogs is a unique combination of the insecticide imidacloprid and the endectocide moxidectin, that provides a broad spectrum of activity against internal and external parasites with the moxidectin component demonstrating high levels of efficacy against a range of stages and species of intestinal nematodes (Cruthers et al. 2008) , including microfilariae of D. immitis (Hendrix et al. 1992 ). The effectiveness of 10 % imidacloprid / 2.5 % moxidectin in the treatment of dogs with micro filaria of D. repens has been demonstrated (Hellman et al. 2011; Traversa et al. 2011) . Most preventive canine heartworm products are not given at dosages designed to be completely microfilaricidal (Bowman and Atkins 2009) . It has been shown that, when moxidectin was given at a lower dosage (3 µg/kg body weight), it did not demonstrate marked microfilaricidal activity, but with a higher dosage showed an effect on mff after repeated administration (Hendrix et al 1992) . Therefore, an increased dosage is necessary for macrocyclic lactones because microfilariae are typically less susceptible than immature (L3, L4) filariid larvae (Bowman 2012) . Moxidectin is a highly lipophilic macrocyclic lactone, that is stored mainly in fat tissues (Al-Azzam et al. 2007 ) and achieves high plasma concentrations with gradual elimination from the host (Blagburn et al. 2009 ). Even though avermectins and milbemycins contain a common macrocyclic lactone ring, they display different ranges of potency, activity and pharmacokinetics (Prichard and Roulet 2005) . Some avermectins and moxidectin have unique characteristics that allow for greater flexibility in use. The longer half-life and safety profile of moxidectin allows it to be used in long-acting formulations (Prichard et al. 2012) , and interest has shifted on moxidectin as a filaricide (Geary and Mackenzie 2011 
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